Skip to main content

Table 1 The representative experiment of hematologic evaluation

From: Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model

 

RBC (106/μl)

Platelets(106/μl)

WBC(103/μl)

Neutrophils(103/μl)

Lymphocytes(103/μl)

Saline

10.8 ± 1.7

1.6 ± 0.2

10.8 ± 3.2

4.1 ± 2.2

4.6 ± 2.5

Honokiol

9.2 ± 2.1

1.6 ± 0.4

10.2 ± 2.4

4.0 ± 1.5

4.2 ± 1.8

DDP

9.2 ± 2.6

1.5 ± 0.5

8.9 ± 2.1

3.6 ± 1.3

3.2 ± 2.3

Honokiol

     

plus DDP

9.1 ± 3.3

1.5 ± 0.7

8.8 ± 2.8

3.8 ± 1.7

3.3 ± 1.9

  1. RBC, platelets, WBC, neutrophils and lymphocyte counts were performed before therapy and at weekly intervals for 4 weeks. The administration of liposomal honokiol plus DDP was described in the Materials and Methods section, The treatment with honokiol, DDP or the combined did not show the significant decrease of the cell counts on day 14 after the therapy, compared with saline alone(P > 0.05), as shown in the table. The similar results were found on day 7, 21, 28 after the therapy.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us